Clinical trials: Acute Cerebral Infarction
Acute Stroke, Cerebral Infarction
ICTUS Study: International Citicoline Trial on Acute Stroke
Citicoline is a safe drug approved in some countries for the treatment of acute ischemic stroke. The drug has shown some evidence of efficacy in a pooled analysis, based on four clinical trials done in USA with oral…
- Trial name
- ICTUS (NCT00331890)
- Testing
- Citicoline
- Where
- 65 sites in Germany, Portugal and 1 more
- Volunteers
- 2,298 people
- Sponsor
- Ferrer Internacional S.A.
Thrombosis, Acute Coronary Syndrome
Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and…
- Conditions
- Thrombosis, Acute Coronary Syndrome, Myocardial Infarction, Stroke
- Trial name
- PR-15/01 (NCT01042964)
- Testing
- revacept (PR-15)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdvanceCor GmbH
Acute Ischemic Stroke
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting…
- Trial name
- NCT01694381
- Testing
- M5, C1-inhibitor
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TSI, LLC
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Cerebral Ischemia
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00141011
- Testing
- Ancrod (Viprinex)
- Where
- 100 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Neurobiological Technologies
Acute Ischemic Stroke
Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)
To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous…
- Trial name
- TRON1-Japan (NCT02964702)
- Testing
- Thrombectomy Device T-01
- Where
- 13 sites in Japan
- Volunteers
- 50 people
- Sponsor
- JIMRO Co., Ltd.
Ischemic Stroke
Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct
The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to…
- Trial name
- NCT05008588
- Testing
- Conditioned Medium, Umbilical Cord Mesenchymal Stem Cells, Neurologic and Neutrophic Drugs
- Where
- 2 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb